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We have shown previously that collagen V (col(V)) autoim-
munity is a consistent feature of atherosclerosis in human cor-
onary artery disease and in the Apoe/mouse model. We have
also shown sensitization of Apoe/ mice with col(V) to mark-
edly increase the atherosclerotic burden, providing evidence of a
causative role for col(V) autoimmunity in atherosclerotic patho-
genesis. Here we sought to determine whether induction of
immune tolerance to col(V)might ameliorate atherosclerosis, pro-
viding further evidence for a causal role for col(V) autoimmunity in
atherogenesis and providing insights into the potential for immu-
nomodulatory therapeutic interventions. Mucosal inoculation
successfully induced immunetolerance tocol(V)withanaccompa-
nying reduction in plaque burden in Ldlr/mice on a high-cho-
lesterol diet. The results therefore demonstrate that inoculation
with col(V) can successfully ameliorate the atherosclerotic burden,
suggesting novel approaches for therapeutic interventions. Sur-
prisingly, tolerance and reduced atherosclerotic burdenwere both
dependent on the recently described IL-35 and not on IL-10, the
immunosuppressive cytokine usually studied in the context of
induced tolerance and amelioration of atherosclerotic symptoms.
In addition to the above, using recombinant protein fragments, we
were able to localize two epitopes of the 1(V) chain involved in
col(V) autoimmunity in atherosclerotic Ldlr/ mice, suggesting
future courses of experimentation for the characterization of such
epitopes.
Atherosclerosis underlies coronary artery disease (CAD)3
and stroke, major global causes of death (1), and is a chronic
inflammatory disease that is modulated by both innate and
adaptive immune pathways. It is increasingly accepted that
autoimmunityconstitutes someportionof thepathologicalpro-
cesses underlying atherosclerosis, with oxidized LDLs, native
lipoproteins, and heat shock proteins identified as autoantigens
involved in atherogenesis (1–8). Recognition of the autoim-
mune aspects of atherosclerosis has suggested the possibility of
employing immunomodulatory approaches to ameliorate
symptoms. That such an approach is feasible has been borne
out in studies in which blockage of T cells reactive to native
lipoprotein ApoB100 (4) or mucosal or subcutaneous immuni-
zation with HSP65 (9, 10), oxidized LDL (11), native 2-glyco-
protein I (12), or apolipoprotein B-100 peptide (13, 14) have
been shown to be atheroprotective.
Collagens can compose up to 60%of the total protein content
in atherosclerotic plaques (15) and stimulate the growth and
inflammation of atheromas (16). We have shown previously
that interleukin 17-dependent autoimmunity to type V colla-
gen col(V)) is a consistent feature of atherosclerosis in
advanced CAD in humans and in Apoe/ mice on a high-fat
diet (17). Moreover, the same study provided evidence of a
causative role for col(V) autoimmunity in the pathogenesis of
atherosclerosis because sensitization of Apoe/mice on nor-
mal chow to col(V) has been shown to markedly increase the
atherosclerotic burden (17). Col(V) is broadly expressed as
1(V)22(V) heterotrimers that are sequestered within the
interiors of fibrils of the abundant type I collagen (col(I)) (18).
However, excessive amounts of 1(V) chains have been shown
to be deposited in atheromas (19), andwhen1(V) chains are in
excess compared with available 2(V) chains with which to
complex, the former can form aberrant 1(V)3 homotrimers
(20) that may be excluded from col(I) fibrils (21). These consid-
erations, and the finding of immune reactivity to 1(V) but not
2(V) chains in atherosclerotic humans and mice, led us previ-
ously to suggest a model in which 1(V)3 homotrimers, in the
inflammatory environment of atherosclerotic plaques, present
normally cryptic epitopes that initiate autoimmunity (17).
Here we present new evidence of a causative role for col(V)
autoimmunity in the pathogenesis of atherosclerosis and for
possible novel immunomodulatory approaches for ameliorat-
ing atherosclerosis by demonstrating that mucosal col(V)
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administration induces immune tolerance and an accompany-
ing reduction in plaque burden in Ldlr/ mice on a high-fat,
high-cholesterol diet. Interestingly, we show both induction of
immune tolerance to col(V) and reduction of the plaque burden
to be dependent on the relatively recently described immuno-
suppressive cytokine IL-35 (22–24). In addition, use of recom-
binant fragments localizes two autoimmune epitopes in the
N-terminal half of the 1(V) triple-helical domain.
Experimental Procedures
Mice—Ldlr/ mice (strain B6.129S7-Ldlrtm1Her/J) were
obtained fromThe Jackson Laboratory, and TV-DTH recipient
C57BL/6 mice were obtained from Harlan Sprague-Dawley.
Five-week-old mice were inoculated intranasally with 4 g of
bovine col(V) (a gift from ImmuneWorks Inc.), 4 g of col(I)
(PureCol, Advanced BioMatrix), or PBS every other day for 2
weeks while on normal chow (Harlan Teklad 8604) and then
placed on a “Western” high-fat (20 gram percent), 1.25% cho-
lesterol diet (D12108C, Research Diets) for 14 or 24 weeks and
inoculated two times per week for the duration of the experi-
ment. A subset of the col(V)-treatedmice for the 24-week study
was subjected to intraperitoneal injection with 100 g of
murine anti-mouse Ebi3 antibody (antibody V1.4C4.22 (25)) or
with isotype-matched control murine IgG2b at 12 weeks sub-
sequent to the start of the Western diet and then with 50 g of
anti-EBi3 or IgG2b once per week until sacrifice. Two weeks
prior to sacrifice, all mice were immunized subcutaneously in
the inguinal regionwith 1.5 limits of flocculation tetanus toxoid
and diphtheria (TT/DT) pediatric vaccine (Sanofi-Aventis Pas-
teur). Upon sacrifice, spleens and aortas were collected and
processed. The experiments were performed in accordance
with National Institutes of Health and United States Depart-
ment of Agriculture guidelines after approval by the University
of Wisconsin Institutional Animal Care and Use Committee.
Trans Vivo Delayed-type Hypersensitivity (TV-DTH) Assay—
TV-DTH assays were performed by cotransfer of 8–10  106
mouse splenocytes into the footpads of naïve C57BL/6 recipi-
ents, as described previously (26). TT/DT (0.25 limits of floc-
culation, Sanofi-Aventis Pasteur) was used as a positive control
recall antigen. Bovine col(V) (ImmuneWorks Inc.) and col(I)
(PureCol, Advanced BioMatrix) were tested at 20 g each.
Cytokines were neutralized by coinjection of 1g of antibodies
against mouse IFN-, IL-17A, TGF- (BD Biosciences), IL-10,
IL-27 p28, IL-12/IL-35 p35 (R&D Systems), and Ebi3 (antibody
V1.4C4.22) (25).
Atherosclerotic Plaque Burden—After euthanasia, aortas
were perfused to remove residual blood by puncturing the left
ventricle with a 25-gauge needle, followed by slow perfusion
with PBS. Fat was dissected away, and a midline incision was
created along the length of the aorta from the diaphragm
through the lesser curvature of the arch. Aortic branches were
removed, and an incision wasmade along the greater curvature
of the arch from theheart to the left subclavian artery. The aorta
was then removed from the body and pinned open on blackwax
for fixation and Oil Red O (ORO) staining, as described previ-
ously (27). Briefly, aortas were rinsed with 78%methanol, incu-
bated for 50 min in ORO stock solution (0.2% weight/volume
ORO, 78% methanol mixed with 22% volume 1 M NaOH and
filtered), destained for 5 min in 78%methanol, and then placed
in PBS. Aortas were photographed under a dissecting micro-
scope at7 magnification. Plaque areas in the descending tho-
racic aortas, from the left subclavian artery to the diaphragm,
were quantified using Photoshop, with the Color Range func-
tion used to identify areas of positive ORO staining. To prevent
bias, the same Color Range settings were used for all analyses.
Percent plaque area was calculated by the number of pixels
selected by the Color Range function divided by the total num-
ber of pixels of the aorta.
Immunoblots—For blots of aortas, to compensate for varia-
tions in the extent of plaque burden between the aortas of
col(V)-, PBS-, and col(I)-treated Ldlr/ mice, plaques were
removed from en face prepared descending thoracic aortas by
forceps prior to extraction of the aortas in SDS-PAGE sample
buffer. For blots of inguinal lymph nodes, the nodes were dis-
sected out and extracted in SDS-PAGE sample buffer. Aorta
blots were probed with mouse monoclonal anti-MCP-1 pri-
mary antibodies (eBioscience) and secondary goat anti-mouse
IgG antibodies (Jackson ImmunoResearch Laboratories,
1:6000). The antibodies for lymph node blots were as described
above, except for the anti-p40 antibody, which was from BD
Biosciences. Blots on PVDF membranes were repeated twice
for aorta blots with similar results. Lymph node blots were
repeated three times with samples from three different mice,
with similar results. All blots were visualized using the ECL kit
(Pierce). Anti-tubulin antibodies for loading controls were
from Millipore. All primary antibodies were diluted 1:1000.
Secondary goat anti-rabbit IgG was diluted 1:4000 (Bio-Rad).
Flow Cytometry—Aortic single-cell suspensions were pre-
pared and stained for lineage markers (B220(RA3-6B2), CD8
(53-6.7), CD4 (RM4–5), NK1.1 (PK136), Ter-119 (TER-119),
Ly6G (1A8), andCD90.2 (53-2.1)) andwith antibodies to deter-
mine monocyte populations, including CD11c (N418), CD11b
(M1/70), and F4/80 (BM8), essentially as described by Dutta
et al. (28). Myeloid cells were defined as lineage-negative/
CD11b populations. Inflammatory monocytes were further
discriminated bymyeloid cells that were F4/80-negative/Ly-6C
positive. All data were acquired on a LSRII flow cytometer (BD
Biosciences) and analyzed using Flowjo data analysis software
(TreeStar).
Production and Purification of Col(V) Recombinant Protein
Fragments—Recombinant DNA expression constructs for pro-
ducing six fragments of similar lengths that, together, consti-
tute the sequences of themajor triple-helical (COL1) domain of
the human 1(V) collagen chain were produced by PCR ampli-
fication from a full-length human pro-1(V) cDNA clone (29)
using the following oligonucleotide primers: fragment 1,
5-CTAGCTAGCTGGACCAGCTGGCCCGATG-3 (forward)
and 5-CCCTTCGAACTGGGGACCCACATTTCCTT-3
(reverse); fragment 2, 5-CTAGCTAGCTGGAGAGCCTGG-
CCCCC-3 (forward) and 5-CCCTTCGAAACCTCCGCGA-
CCCTTTGG-3 (reverse); fragment 3, 5-CTAGCTAGCTAA-
TGGTGACCCCGGTCCTCT-3 (forward) and 5-CCCTTC-
GAACGGAAGCCCCTGTTCACC-3 (reverse); fragment
4, 5-CTAGCTAGCTGGCCTTGCTGGAAAAGAAGGG-3
(forward) and 5-CCCTTCGAAGGGACCTTCATCACCTT-
TCTGC-3 (reverse); fragment 5, 5-CTAGCTAGCTAGAG-
IL-35-based Collagen V Immune Tolerance and Atherosclerosis
3360 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 7•FEBRUARY 12, 2016
GCTTTCCTGGACCCC-3 (forward) and 5-CCCTTCGAA-
CGATGGACCTGGTTCACCAGT-3 (reverse); and fragment
6, 5-CTAGCTAGCTGGGCCTCCAGGAAAAAGGGG-3
(forward) and 5-CCCTTCGAAGATTGGCAGGGGCTGGA-
TGA-3 (reverse). In each case, NheI and BstBI restriction sites
were added to the 5 and 3 ends of each fragment, respectively.
The PCR products were then ligated between NheI and BstBI
sites of a modified pcDNA4 vector (Life Technologies), con-
taining sequences encoding a BM40 signal peptide (to optimize
secretion) directly 5 of the NheI restriction site and a His6 tag
directly 3 of the BstBI restriction site. Additionally, sequences
encoding the pro-1(V) C-propeptide were added 3 to each of
the fragments to enable chain association and the formation of
triple-helical molecules. The primer set 5-CCCTTCGAAAA-
CATCGACGC-3 (forward) and 5-CCCTTCGAAGCCCAT-
GAAGCA-3 (reverse) was used to amplify C-propeptide
sequences from the full-length human pro-1(V) clone
described above, adding BstBI sites to both the 5 and 3 ends.
The PCR product was then ligated into each of the previously
constructed vectors at the single BstBI site. Several clones of
each fragment construct were sequenced to ensure proper ori-
entation of the C-propeptide insert.
Purified constructs were transfected with TransIT-LT1
(MirusBio,Madison,WI) intoT-RExHEK293 cells, followed by
selection for zeocin resistance. Cells were maintained in
DMEM (Cellgro, Manassas, VA) supplemented with 10% FBS
(MidSci, Valley Park, MO) in 5% CO2. To obtain conditioned
media for harvesting, cells were first rinsed twice with PBS and
then serum-starved in DMEM supplemented with 75 g/ml
ascorbic acid, 40 g/ml soybean trypsin inhibitor (Sigma), and
1 g/ml tetracycline. Conditioned media were collected every
24 h for 3–5 consecutive days and supplemented with 0.1 mM
phenylmethylsulfonyl fluoride, 1 mM N-ethylmaleimide, and
0.1mM p-aminobenzoic acid. Themediumwas then purified on
Co2 columns (Thermo Scientific, Waltham, MA). Eluents were
dialyzed against PBS. Purity and quantification were determined
by SDS/PAGE gel stained with Coomassie Brilliant Blue.
Statistical Analysis—Data were analyzed using GraphPad
Prism 5 software (GraphPad Software, La Jolla, CA). Unpaired
Student’s t tests were used for all other analyses.
Results
Mucosal Administration of ColV Induces Tolerance in
Ldlr/ Mice on a Western Diet—In initial experiments to
determine whether mucosal administration of colV might
induce tolerance to this autoantigen in atherosclerotic mice,
5-week-old Ldlr/ mice on normal chow were treated with
small-volume nasal infusions of colV or, as negative controls,
PBS or col(I). After 2 weeks, the mice were shifted to a high-fat,
high-cholesterolWestern diet (Fig. 1A) to induce atherosclero-
sis. All mice were also immunized with TT/DT to provide a
positive control for immunity. Preliminary studies employing
TV-DTH assays of splenocytes indicated that col(V) autoim-
munity becomes consistently detectable in Ldlr/ mice after
12 weeks on the Western diet (data not shown). Therefore,
after 14 weeks on the Western diet, col(V)-, col(I)-, and PBS-
treated Ldlr/ mice were sacrificed, and their splenocytes
were tested for anti-col(V) cellular immunity via TV-DTH
assay. Splenocytes obtained from all differently treated Ldlr/
mice exhibited a high immunoreactivity to the TT/DT control
antigen, indicative of intact immune systems (Fig. 1, B–D). In
addition, Ldlr/ mice that were treated with PBS or col(I)
showed substantial immune reactivity to col(V) but no reactiv-
ity to col(I) (Fig. 1, B and C), a collagen that, although present
abundantly in atherosclerotic lesions (30), does not appear
to act as an autoantigen (17). In contrast, Ldlr/ mice that
were administered col(V) showed a lack of immune reactiv-
ity to col(V) (Fig. 1D), consistent with induced immune
tolerance.
When splenocytes from the PBS- or col(I)-treated Ldlr/
mice were co-injected with neutralizing antibodies to IFN- in
TV-DTH assays, immune responses to col(V) were blocked sig-
nificantly for splenocytes from the PBS-treated mice (Fig. 2A),
with a trend toward reduced immunity to col(V) for splenocytes
from col(I)-treated mice (Fig. 2B). Immune responses to col(V)
were blocked more effectively and consistently in TV-DTH
assays via co-injection of splenocytes fromeither PBS- or col(I)-
treated Ldlr/mice with neutralizing antibodies to IL-17 (Fig.
2, A and B). These results suggest a variable dependence of the
anti-col(V) response on the Th1 pathway and a more consis-
tent, stronger dependence on the Th17 pathway. These results
are consistent with those obtained previously using atheroscle-
rotic Apoe/mice, which also demonstrated a col(V) autoim-
munity with consistent dependence on the Th17 pathway and
more variable involvement of the Th1 pathway (17). Therefore,
the immune pathways involved in atherosclerosis-associated
anti-col(V) immunity seem to be similar in these two mouse
models.
Induced Tolerance to Col(V) Is Regulated by IL-35 but Not by
IL-10 or TGF-1—We have shown previously that Apoe/
mice on normal chow have an IL-10-suppressed anti-col(V)
autoimmune response associatedwith incipient atherosclerosis
(17). To characterize the nature of the tolerance induced in the
col(V)-treated Ldlr/mice and determine the extent to which
it might be mediated by IL-10-producing cells, splenocytes
from the col(V)-treated Ldlr/ mice were co-injected in the
TV-DTH assay with col(V) with or without neutralizing anti-
bodies to IL-10 or to another immunosuppressive cytokine,
TGF-1. Surprisingly, neutralization of IL-10 or TGF-1 did
not have any effect on the TV-DTH swelling response (Fig. 2C)
and, therefore, no effect on tolerance.We then sought to deter-
mine the extent to which this tolerance might be mediated by
the more recently characterized immunosuppressive cytokine
IL-35 (22–24). IL-35 is a unique heterodimer comprising sub-
units p35 and Ebi3. However, p35 is also found, along with the
subunit p40, in the heterodimeric pro-inflammatory cytokine
IL-12, whereas Ebi3 is also found, alongwith the subunit p28, in
the heterodimeric cytokine IL-27, which can both promote and
suppress effector T cell responses, depending upon the
microenvironment (24). Therefore, to test for a possible role for
IL-35 in the tolerance induced in col(V)-treated Ldlr/mice,
we co-injected splenocytes from these mice with neutralizing
antibodies to p35 or Ebi3.We also co-injected splenocytes with
antibodies to p28 to demonstrate that effects on anti-col(V)
responsiveness from co-injection of splenocytes with anti-Ebi3
were due to neutralization of Ebi3-containing IL-35 and not
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due to neutralization of Ebi3-containing IL-27. Neutralization
of either p35 or Ebi3 was sufficient to break the tolerance (Fig.
2D), whereas neutralization of both p35 and Ebi3 together did
not produce a greater effect on the TV-DTH swelling response
than neutralization of either subunit separately. This lack of an
additive effect is consistent with the conclusion that effects on
TV-DTHswellingwere solely via neutralization of p35 andEbi3
subunits found in the same population of p35/Ebi3 het-
erodimers (i.e. IL-35) and did not include effects of neutraliza-
tion of p35 or Ebi3 bound to other types of subunits in other
cytokines. This conclusion was bolstered by the finding that
neutralization of p28, bound to Ebi3 in IL-27 heterodimers but
not found in IL-35 heterodimers, had no effect on TV-DTH
swelling responses (Fig. 2D).Moreover, the anti-Ebi3monoclo-
nal antibodies used for this study have been shownpreviously to
neutralize only IL35 and not IL-27 (22), even though both con-
tain Ebi3 chains. Therefore, the induced tolerance to col(V) in
col(V)-treated Ldlr/mice is mediated by IL-35.
In support of the possibility that the induced tolerance to
col(V) in col(V)-treated mice is mediated by IL-35, immuno-
blotting of inguinal lymph nodes showed increased levels of
both IL-35 subunits, Ebi3 and p35, in the lymphocytes of
col(V)-inoculated mice compared with levels in the lympho-
cytes of PBS- and col(I)-inoculated mice (Fig. 3, A–C). That
this increase is specific for IL-35 and does not also reflect
increases in IL-12 or IL-27, which also contain p35 and Ebi3
subunits, respectively, was demonstrated by showing that
neither IL-12 subunit p40 nor IL-27 subunit p28 was ele-
vated in the lymph nodes of col(V)-inoculated mice (Fig. 3,
A–C).
Induced Tolerance to Col(V) Can Ameliorate the Atheroscle-
rotic Burden—We have shown previously that sensitization of
Apoe/mice onnormal chow to col(V) breaks the tolerance to
col(V), resulting in exacerbated atherosclerosis (17). This pro-
vided evidence that col(V) autoimmunity can play a causal role
in the pathogenesis of atherosclerosis. To determine whether
inducing tolerance to col(V) in Ldlr/mice on aWestern diet
might ameliorate atherosclerosis, the plaque burden was com-
pared in the descending thoracic aortas of PBS-, col(I)-, and
col(V)-treated Ldlr/mice after 14 weeks on a Western diet.
ORO staining showed a significant reduction in plaque burden
in col(V)-treated Ldlr/ mice, which had a percent plaque
FIGURE 1.Mucosal administration induces tolerance to col(V) in Ldlr/mice on aWestern diet. A, schematic relating the beginning of col(V) inoculation
of Ldlr/mice onnormal chowwith placing themice on aWestern diet, injectionswith anti-Ebi3 antibodies, and times of sacrifice. B–D, Ldlr/micewere fed
aWestern diet for 14 weeks before experimentation. All mice were immunized with TT/DT 2 weeks before the assays. TV-DTHmeasured cellular responses to
TT/DT, col(V), andcol(I) by splenocytes frommice treatednasallywithPBS (B,n8mice/assay), col(I) (C,n6mice/assay), andcol(V) (D,n8mice/assay). Data
are shown as mean S.E. ***, p 0.0005; NS, not significant.
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area reduced by 47% and 37% compared with PBS- and col(I)-
treated Ldlr/mice, respectively (Fig. 2E). This provides fur-
ther evidence of a causal role for col(V) autoimmunity in the
pathogenesis of atherosclerosis.
Amelioration of the Atherosclerotic Burden by Induced Toler-
ance to Col(V) Is IL-35-dependent—Because neutralizing anti-
bodies to IL-35 can break immune tolerance to col(V) in TV-
DTH assays (Fig. 2D), we tested whether IL-35-neutralizing
antibodiesmight also be able to break in vivo tolerance to col(V)
autoimmunity inLdlr/mice on aWestern diet and, if so, how
this breaking of tolerance might affect the plaque burden.
Toward this end, Ldlr/mice were nasally administered PBS,
col(I), or col(V) and kept on a Western diet for 24 weeks. One
cohort of the col(V)-treated Ldlr/ mice was subjected to a
regimen of injections with monoclonal anti-Ebi3 antibody,
shownpreviously to neutralize IL-35 (22), and anotherwas sub-
jected to injections with isotype-matched control murine IgG.
As with mice kept on the Western diet for 14 weeks (above),
PBS- and col(I)-treated mice on the Western diet for 24 weeks
showed IL-17-dependent and, to a lesser degree, IFN--depen-
FIGURE2. Inducedcol(V) tolerance is regulatedby IL-35butnotby IL-10orTGF-1. Ldlr/micewere fedaWesterndiet for 14weeks andwere immunized
with TT/DT 2 weeks before the assays. TV-DTH assays compared T cell responses between splenocytes injected with col(V) alone or in the presence of
neutralizing antibodies to cytokines. A and B, TV-DTH responses were compared for splenocytes from PBS-treated mice (A, n  8 mice/group) and from
col(I)-treatedmice (B, n 6mice/group) injectedwith col(V) alone or togetherwith neutralizing antibodies to IFN-or IL-17.C, splenocytes fromcol(V)-treated
Ldlr/ mice kept on a Western diet for 14 weeks were injected with TT/DT, with col(V) or col(I) alone or together with control IgG, or with neutralizing
antibodies to TGF- or IL-10 (n 8mice/group).D, splenocytes from col(V)-treated Ldlr/mice kept on aWestern diet for 14weekswere injectedwith TT/DT,
or with col(V) alone (n 6) or together with neutralizing antibodies to p28 (a subunit of IL-27 but not IL-35), p35 (a subunit of both IL-35 and IL-12), or Ebi3 (a
subunit of both IL-35 and IL-27), or together with both p35 and Ebi3 (n 6mice/group). E, quantitative analysis of the percent of plaque area in ORO-stained
en face preparations of the descending aortas of Ldlr/mice treated nasally treated with PBS, col(I), or col(V) andmaintained on aWestern diet for 14 weeks
(for each group, n 8 mice). Data are shown as mean S.E. *, p 0.05; **, p 0.005; ***, p 0.0005; NS, not significant.
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dent immune reactivity to col(V) in TV-DTH assays (Fig. 4). All
mice in the col(V)-treated group subjected to injections with
control IgGwere tolerized to col(V), with tolerance shown to be
IL-35-dependent via use of TV-DTH assays (Fig. 5A). In con-
trast, none of the col(V)-treated Ldlr/ mice subjected to
injections with anti-Ebi3 antibodies demonstrated evidence of
col(V) tolerance, showing instead strong col(V) immunity with
significant IL-17 dependence and a trend suggestive of some
dependence on IFN- (Fig. 5B). These results strongly support
the conclusion that in vivo col(V) immune tolerance, induced
by mucosal col(V) administration, is IL-35-dependent.
Importantly, col(V)-treated Ldlr/mice injected with anti-
Ebi3 antibodies did not show the reduction in atherosclerotic
plaque burden seen in col(V)-treated Ldlr/ mice injected
with IgG (Fig. 5, C and D) or in col(V)-treated Ldlr/mice in
the experiments in which mice were kept on the Western diet
for 14 weeks (above). In fact, the percent of plaque area was
increased significantly in the aortas of col(V)-treated athero-
sclerotic Ldlr/mice injected with anti-Ebi3 antibodies com-
pared with the percent of plaque area found in the aortas of
PBS- and col(I)-treated atherosclerotic Ldlr/mice (Fig. 5, C
and D). This suggests that neutralizing antibody to Ebi3 not
only blocked col(V) tolerance, but likely other immunosuppres-
sive effects of IL-35 as well. It should be noted again that
although signaling via the IL-27 receptor appears capable of
playing an anti-atherosclerotic role (31), the anti-Ebi3 mono-
clonal antibody used in the present study does not appear capa-
ble of blocking IL-27 (22), even though the latter, like IL-35,
contains the Ebi3 subunit.
To gain further insights into the effects of induced col(V)
tolerance on atherosclerotic pathology, we analyzed the levels
of MCP-1, a chemokine (expressed by vascular endothelial
cells, smooth muscle cells, and macrophages) that is increased
in atherosclerotic lesions and is key in initiating and propagat-
ing the inflammatory process underlying atherogenesis (32).
Interestingly, MCP-1 levels were reduced greatly in the aortas
of col(V)-treated atherosclerotic Ldlr/ mice subjected to
injections with IgG (Fig. 5E). In contrast, MCP-1 levels were
high in the aortas of atherosclerotic Ldlr/mice subjected to
anti-Ebi3 antibody injections, with levels similar to those found
in the aortas of atherosclerotic Ldlr/ mice treated with PBS
or col(I) (Fig. 5E). Therefore, the in vivo col(V) immune toler-
ance induced by mucosal administration of col(V) induces
reductions in atherosclerotic plaque burden and in levels of a
cytokine that is key in vessel inflammation, and, in both cases,
these reductions seem to be IL-35-dependent.
When total numbers of CD11b monocytes/macrophages
were ascertained in the aortas of mice treated with PBS or
treated with col(V) and then subjected to injections with IgG or
with anti-Ebi3 antibodies, the col(V)-treatedmice injectedwith
IgG were found to have a significant decrease in CD11b cells
compared with the PBS-treated controls whereas, in contrast,
col(V)-treated mice injected with anti-Ebi3 antibody did not
(Fig. 5F). However, although there was a trend towardmoreCD
11b cells in the aortas of anti-Ebi3-injected mice than in the
aortas of IgG-injected mice, the difference did not reach signif-
icance. In contrast, aortas of the anti-Ebi3-injected mice had
markedly and significantly increased numbers of Ly-6Chigh
inflammatory (28) CD11b monocytes/macrophages com-
pared with the aortas of IgG-injected mice (Fig. 5F). Therefore,
MCP-1 levels (Fig. 5E) correlated with levels of Ly-6Chigh
inflammatory CD11bmonocytes/macrophages (Fig. 5F), and
both were reduced by induction of IL-35-dependent tolerance
to col(V).
Epitopes Underlying Col(V) Autoimmunity in Ldlr/ Mice
Are Localized to the N-terminal Half of the 1(V) Triple-helical
Domain—We have shown previously that the epitopes under-
lying col(V) autoimmunity in both human CAD and bronchi-
olitis obliterans syndromemap to the1(V) chain triple-helical
domain (17, 33). Toward further locating and characterizing
such epitopes, recombinant fragments representing essentially
the entire human 1(V) chain triple-helical domain divided
into six fragments of similar length (Fig. 6, A and B) were
subjected to TV-DTH assays with splenocytes from
Col5a2loxP/loxP:Ldlr/ mice that had been on a Western diet
for 24 weeks. As can be seen in Fig. 6C, only fragments 1 and 3
garnered immune responses, and these were 67% that of
intact col(V). Fragments 1 and 3 comprise amino acids 41–156
and 294–471, respectively, of the 1014-amino acid triple-heli-
cal domain (Fig. 7). Previously, Keller et al. (34) have screened a
library of 101 overlapping 15-mer peptides spanning the
human 1(V) chain triple-helical domain, employing an assay
that identifies conformational changes induced inMHCclass II
molecules upon binding to peptide epitopes. Only two of the
FIGURE 3. Levels of the IL-35 subunits Ebi3 and p35 are increased in the inguinal lymphnodes of col(V)-treatedmice. A, representative immunoblots of
inguinal lymphnodesprobedwith antibodies to Ebi3, p35, p28, p40, and tubulin, the latter as a loading control.B andC, quantificationof the intensity of bands
for Ebi3 (B) and p35 (C) for three immunoblots of inguinal lymph nodes from three different mice. *, p 0.05; **, p 0.005; ***, p 0.0005.
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101 peptides of that assay bound human DQ molecules and
H2-I-Ab, the DQ-like MHC class II equivalent present in
C57BL/6 mice, the background employed this study. Interest-
ingly, one of these peptides (p599) is located within recombi-
nant fragment 1 and the other (p909) within fragment 3, con-
sistent with the possibility that these two fragments contain
immunologically relevant epitopes recognized by DQ-like
MHC class II molecules. Peptides p599 and p909 from the pre-
vious study (34) are shown, like recombinant fragments 1 and 3
from this study, to garner immune responses in splenocytes
from Col5a2loxP/loxP:Ldlr/mice that had been on a Western
diet for 24 weeks (Fig. 6C). Because the experiments described
here employ bovine and human 1(V) fragments and peptides
from the 1(V) major triple-helical domain in a mouse model,
we note that sequences of this domain are highly conserved
across mammalian species, with 98% identity between mouse
and either bovine or human COL1 sequences. All three species
are identical for sequences corresponding to peptide p909,
whereas human and bovine are identical for sequences corre-
sponding to peptide p599, and mouse sequences differ at one
residue (PPGPTGKPGRRG for mouse, PPGPAGKPGRRG for
human and bovine) for this peptide.
Discussion
It is increasingly apparent that proinflammatory processes
that affect atherosclerotic plaque growth and destabilization
and that perpetuate/amplify the inflammatory state in this dis-
ease involve autoimmune responses that develop in the lesion
against local self-antigens. Documented local self-antigens
include heat shock proteins, oxidized LDL, and native lipopro-
teins (1–8). Most recently, we have demonstrated autoimmu-
nity to the 1(V) chain of col(V) to be a consistent feature of
atherosclerosis in human CAD and in the Apoe/ mouse
model (17). Moreover, sensitization of Apoe/mice to col(V)
via intravenous injection, which intensified anti-col(V) immu-
nity, also exacerbated the plaque burden. This result was con-
sistent with the conclusion that col(V) autoimmunity can play a
causal role in the pathogenesis of atherosclerosis (17). Here we
extend previous findings by showing that col(V) autoimmunity
is also a feature of atherosclerosis in the Ldlr/mouse. More
importantly, we show that induction of immune tolerance via
mucosal vaccination with col(V) results in a reduced athero-
sclerotic burden in Ldlr/mice on a Western diet, providing
further evidence of causality for col(V) autoimmunity in
atherosclerosis.
In previous studies, intranasal inoculation with HSP65 or an
apolipoprotein B-100 peptide or oral feedingwith2-glycopro-
tin I resulted in some degree of amelioration of atherosclerosis
that correlated with indications of increased IL-10 expression
(9, 12–14). However, none of these studies demonstrated a
causative role for IL-10 in the induction of immune tolerance.
In contrast, we show here that induction of col(V) immune
tolerance via nasal inoculation of Ldlr/ mice is IL-10-inde-
pendent and is, instead, dependent on the more recently
described immunosuppressive cytokine IL-35 (22–24). More-
over, reductions in aorta MCP-1 levels and in recruitment to
aortas of Ly-6Chigh inflammatory monocytes/macrophages
(key mediators of the chronic inflammatory response in exper-
imental atherosclerosis (28, 35)) and reductions in plaque bur-
den, all of which were concomitant with induced col(V)
immune tolerance, are also shown to be IL-35-dependent.
Because the percent of plaque area was greater in aortas of
col(V)-inoculatedmice subsequently injectedwith neutralizing
anti-Ebi3 antibodies than in aortas of PBS- or col(I)-treated
controls (Fig. 5C), it is likely that the neutralizing antibody to
Ebi3 not only blocked col(V) tolerance but also blocked other
immunosuppressive effects of IL-35 normally in play in ather-
osclerosis and unrelated to col(V) tolerance.
The in vivo experiments that demonstrated the inoculation-
induced col(V) tolerance and reduction of the atherosclerotic
burden to be IL-35-dependent employed an antibody to Ebi3
that, in addition to being a subunit of IL-35, is also, along with
p28, a subunit of IL-27. However, the anti-Ebi3 monoclonal
antibody used for this study has been shown to neutralize only
IL-35 and not IL-27 (22). Moreover, TV-DTH assays showed
that, although the anti-Ebi3 antibodywas sufficient to break the
tolerance to col(V), anti-p28 antibodies had no effect on col(V)-
FIGURE 4. Ldlr/mice on a Western diet for 24 weeks have IL-17-dependent immune reactivity to col(V). A and B, TV-DTH assays of splenocytes from
PBS-treated (A) and col(I)-treated (B)miceonaWesterndiet for 24weeks and then injected into the footpadswith col(V) aloneor in thepresenceof neutralizing
antibodies to cytokines showed IL-17-dependent and, to a lesser degree, IFN--dependent immune reactivity to col(V). Data are shown as mean S.E.
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induced tolerance (Fig. 2D). Therefore, it may be inferred from
the various data that IL-35 is an important factor involved not
only in the induction of col(V) tolerance demonstrated here but
also in the attempts of the body to counteract the chronic
inflammatory and autoimmune responses associated with pro-
nounced atherosclerosis.
It is clear that an imbalance in the ratio of T regulatory (TR)
and T effector (TE) cells can be an important cause of autoim-
munity (36) and that CD4TR cells play a protective role in the
progression of atherosclerosis (37, 38). In addition to direct
suppressive activity, IL-35 is able, like the other immunosup-
pressive cytokines TGF-1 and IL-10, to expand the breadth of
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suppressive immunity by inducing and mobilizing additional
regulatory cells in a process known as infectious tolerance (24,
39). In the case of IL-35, this includes the induction of naïve and
effector T cells into a distinct population of CD4 TR cells
(iTr35 cells) that mediate immune suppression via IL-35, and
not via either IL-10 or TGF, and that appear to have increased
stability and efficiency relative to IL-10- or TGF-induced TR
cells (25, 39). Because we have shown that the immune toler-
anceinducedbymucosalinoculationofcol(V)isnotonlyIL-35-de-
pendent but also IL-10- and TGF-independent, the data sug-
gest iTr35 cells to be of major importance in establishing/
maintaining the immune tolerance to col(V) that leads to
amelioration of atherosclerosis in Ldlr/ mice. However, we
do not exclude possible roles for other IL-35-secreting cells,
including regulatory B cells andCD8TR cells, whichmay both
mediate immune suppression directly and contribute to the
induction/expansion of iTr35 cells via secretion of IL-35 (24,
39). Although iTR35 cells do not mediate immune suppression
via IL-10, initial induction of iTr35 cells appears to be via the
concerted actions of IL-35 and IL-10 (24, 39). We have previ-
ously provided data that suggested a role for IL-10 in the sup-
pression of col(V) autoimmunity in nascent atherosclerosis
(17). Therefore, IL-10-based suppressivemechanismsmay play
a substantive role in incipient atherosclerotic disease, whereas
IL-35-based suppressivemechanisms appear to predominate in
pronounced atherosclerosis and in the type of therapeutic
induction of tolerance demonstrated here. However, the pres-
ence of IL-10 even in incipient atherosclerotic disease suggests
that IL-10 from activatedTR cells associatedwith atherogenesis
even at its earliest stages would be available for the induction/
expansion of iTR35 cells. Nevertheless, our results, in which
col(V) immune tolerance is shown to be IL-10-independent,
support the conclusion that this IL-10 is not involved in the
maintenance or efficacy of iTr35 populations responsible for
induced col(V) immune tolerance or the resulting amelioration
of atherosclerotic disease.
Previous reports have provided evidence for IL-35 roles in
ameliorating inflammation in various autoimmune and
chronic inflammatory settings. These include mouse models
of inflammatory bowel disease, experimental autoimmune
encephalomyelitis, and collagen II-induced arthritis (39). In
FIGURE 5. Amelioration of the atherosclerotic burden by induced col(V) tolerance is dependent on IL-35. A, in TV-DTH assays, splenocytes from col(V)-
treated Ldlr/mice subjected to injections with IgG and kept for 24weeks on aWestern diet were injectedwith TT/DT (n 7), col(I) plus IgG (n 7), or col(V)
plus IgG (n 7) or plus neutralizing antibodies to p28 (a subunit of IL-27 but not IL-35) (n 6), p35 (a subunit of both IL-35 and IL-12, n 5), or Ebi3 (a subunit
of both IL-35 and IL-27, n 5), or plus both p35 and Ebi3 (n 6). B, in TV-DTH assays, splenocytes from col(V)-treated Ldlr/mice subjected to injectionswith
neutralizing antibodies to Ebi3 and kept for 24weeks on aWesterndietwere injectedwith TT/DT,with col(I) orwith col(V) alone, or plus neutralizing antibodies
to IFN- or IL-17 (n 6 in each case). C, quantitative analysis of the percent plaque area in ORO-stained en face preparations of descending thoracic aortas of
Ldlr/ mice treated nasally with PBS or col(I) or treated nasally with col(V) and then subjected to injections with IgG or neutralizing antibody to Ebi3. D,
representativeORO-stained en facepreparations of descending thoracic aortas. E, immunoblottingwith anti-MCP-1 antibody orwith antibody to-tubulin (as
a loading control) of descending thoracic aortic extracts frommice treated nasally with PBS (P) or col(I) (I) or treated nasally with col(V) and then subjected to
injectionswith IgG or neutralizing antibody to Ebi3. F, representative flowplots (left panels) and flow cytometric quantification (right panels) of the percentage
of CD11bmonocytes/macrophages (top panels) or of Ly-6Chigh inflammatory CD11bmonocytes/macrophages (bottompanels) in the aortas of Ldlr/mice
treated nasally with PBS (n 9) or with col(V) and the latter subjected to injections with IgG (n 8) or neutralizing antibodies to Ebi3 (n 5) andmaintained
for 24 weeks on a Western diet. Data are shown as mean S.E. *, p 0.05; **, p 0.005; ***, p 0.0005; NS, not significant.
FIGURE6.EpitopesunderlyingCol(V) autoimmunity in Ldlr/miceare localized to theN-terminal half of the1(V) triple-helical domain.A, schematic
aligning the six recombinant fragments with the triple-helical region of the 1(V) chain. B, Coomassie-stained SDS-PAGE gel of purified 1(V) recombinant
fragments. Fragments 1–4 ran with the expected mobilities, whereas fragments 5 and 6 had delayed mobilities, presumably because of extensive posttrans-
lational modifications. Molecular masses (in kilodalton) are indicated for protein standards. C, TV-DTH measured T cell responses to 1(V) recombinant
fragments 1–6 and15-mer peptides p599 andp909 (34) using splenocytes fromCol5a2loxP/loxP:Ldlr/mice that hadbeenon aWestern diet for 24weeks. Data
are shown as mean S.E.
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addition, strong co-expression of Ebi3 and p35 in smooth
muscle cells, endothelial cells, and macrophages of advanced
lesions in patients with symptomatic carotid plaques (40)
and positive correlation of plasma IL-35 levels with the left
ventricular ejection fraction in a large number of CAD
patients (41) has led to the hypothesis that IL-35 may be
involved in amelioration of atherosclerosis and improved
prognosis in CAD (42). Here we provide strong evidence that
IL-35 can play a key role in the amelioration of plaque bur-
den in atherosclerosis.
The use of recombinant fragments in this study localizes two
1(V) chain epitopes involved in col(V) autoimmunity in ath-
erosclerotic Ldlr/ mice to between amino acid residues
41–156 and 294–471 of the triple-helical domain. The loca-
tions of these two epitopes correspond to the positions of two
peptides shown previously to bind to human DQ-like MHC
class II molecules and to the C57BL/6 DQ-like murine equiva-
lent H2-I-Ab (34) and shown here to garner immune responses
in splenocytes from atherosclerotic Ldlr/mice. Localization
via two independent approaches of these two epitopes involved
in col(V) autoimmunity and the progression of atherosclerosis
will enable their further characterization.
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